Diabetes and restenosis
Restenosis, defined as the re-narrowing of an arterial lumen after revascularization,
represents an increasingly important issue in clinical practice. Indeed, as the number of stent …
represents an increasingly important issue in clinical practice. Indeed, as the number of stent …
GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far?
MR Pedrosa, DR Franco, HW Gieremek… - Current atherosclerosis …, 2022 - Springer
Abstract Purpose of Review To discuss evidence supporting the use of glucagon-like
peptide 1 receptor agonists (GLP-1RA) to treat obesity and their role as a cardioprotective …
peptide 1 receptor agonists (GLP-1RA) to treat obesity and their role as a cardioprotective …
The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
D Giugliano, M Longo, S Signoriello… - Cardiovascular …, 2022 - Springer
Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose co-
transporter-2 (SGLT-2) inhibitors reduce cardiorenal outcomes. We performed a network …
transporter-2 (SGLT-2) inhibitors reduce cardiorenal outcomes. We performed a network …
Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms
Several randomized controlled trials have demonstrated the benefits of glucagon-like
peptide-1 receptor agonists (GLP-1RAs) on ischemic stroke in patients with diabetes. In this …
peptide-1 receptor agonists (GLP-1RAs) on ischemic stroke in patients with diabetes. In this …
Benefits of GLP-1 (glucagon-like peptide 1) receptor agonists for stroke reduction in type 2 diabetes: a call to action for neurologists
RM Goldenberg, AYY Cheng, T Fitzpatrick, JD Gilbert… - Stroke, 2022 - Am Heart Assoc
People living with diabetes are at higher risk for stroke and have a poorer prognosis
following a stroke event than those without diabetes. Data from cardiovascular outcome …
following a stroke event than those without diabetes. Data from cardiovascular outcome …
Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management
K Khunti, F Zaccardi, A Amod, VR Aroda, P Aschner… - Diabetologia, 2024 - Springer
A panel of primary care and diabetes specialists conducted focused literature searches on
the current role of glycaemic control in the management of type 2 diabetes and revisited the …
the current role of glycaemic control in the management of type 2 diabetes and revisited the …
A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes
R Bouchi, T Kondo, Y Ohta, A Goto… - Journal of Diabetes …, 2023 - Wiley Online Library
In 2020, the Japan Diabetes Society (JDS) adopted a swee** decision to release
consensus statements on relevant issues in diabetes management that require updating …
consensus statements on relevant issues in diabetes management that require updating …
A consensus statement from the Japan Diabetes Society (JDS): a proposed algorithm for pharmacotherapy in people with type 2 diabetes
R Bouchi, T Kondo, Y Ohta, A Goto, D Tanaka… - Diabetology …, 2023 - Springer
In 2020, the Japan Diabetes Society (JDS) adopted a swee** decision to release
consensus statements on relevant issues in diabetes management that require updating …
consensus statements on relevant issues in diabetes management that require updating …
Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized …
Background Effects of antihyperglycemic therapies on cardiovascular and heart failure (HF)
risks have varied widely across cardiovascular outcome trials (CVOTs), and underlying …
risks have varied widely across cardiovascular outcome trials (CVOTs), and underlying …
Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: an eight RCTs meta-analysis
J Wei, B Yang, R Wang, H Ye, Y Wang… - Frontiers in …, 2022 - frontiersin.org
Purpose To explore the risk of stroke (including ischemic and hemorrhagic stroke) in type 2
diabetes mellitus treated with glucagon-like peptide 1 receptor agonist (GLP-1RA) …
diabetes mellitus treated with glucagon-like peptide 1 receptor agonist (GLP-1RA) …